[ad_1]
VANCOUVER and MINNEAPOLIS – 
the Higher Regional Court in Munich, Germany has upheld the first
instance judgment of the Regional Court Munich of June 16, 2017, in which the
court had found that Edwards Lifesciences LLC (“Edwards”) had
contributed in part to the invention of the Tiara™ and awarded to Edwards
co-entitlement rights to the disputed Tiara™ European patent application. There
are no monetary awards associated with these matters and no damages award was
recognized.
Neovasc is currently reviewing
its possibilities for appeal.
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for the rapidly
growing cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially available
in the United States and has been commercially available in Europe since 2015,
and Tiara™ for the transcatheter treatment of mitral valve disease, which is
currently under clinical investigation in the United States, Canada, Israel and
Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Forward-Looking Statement
Disclaimer
Certain statements in this news
release contain forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used herein, the
words “expect”, “anticipate”, “estimate”,
“may”, “will”, “should”, “intend,”
“believe”, and similar expressions, are intended to identify
forward-looking statements. Forward-looking statements may involve, but are not
limited to, the Company’s review of its possibilities for appeal
and expectations as to the growing cardiovascular marketplace.
Forward-looking statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical trends,
current conditions and expected future developments, as well as other factors
that the Company believes are appropriate in the circumstances. Many factors
could cause the Company’s actual results, performance or achievements to differ
materially from those expressed or implied by the forward
looking statements, including those described in the “Risk
Factors” section of the Company’s Annual Information Form and in the
Management’s Discussion and Analysis for the three months ended March 31,
2021 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors should be
considered carefully, and readers should not place undue reliance on the
Company’s forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
[ad_2]